{"id":"efalizumab","rwe":[{"pmid":"41409530","year":"2025","title":"Immune Cell-Targeting Biologics for Alopecia Areata: A New Paradigm in Precision Medicine.","finding":"","journal":"Skin appendage disorders","studyType":"Clinical Study"},{"pmid":"40856907","year":"2025","title":"Management of Erythrodermic Psoriasis with Systemic Therapies: A Systematic Review.","finding":"","journal":"American journal of clinical dermatology","studyType":"Clinical Study"},{"pmid":"40220275","year":"2025","title":"Drug-induced Guillain-Barré Syndrome: a disproportionality analysis based on the US FDA adverse event reporting system.","finding":"","journal":"Expert opinion on drug safety","studyType":"Clinical Study"},{"pmid":"39411068","year":"2024","title":"PBPK-based translation from preclinical species to humans for the full-size IgG therapeutic efalizumab.","finding":"","journal":"Frontiers in pharmacology","studyType":"Clinical Study"},{"pmid":"37496824","year":"2023","title":"Effect of Biologic Therapies on Airway Hyperresponsiveness and Allergic Response: A Systematic Literature Review.","finding":"","journal":"Journal of asthma and allergy","studyType":"Clinical Study"}],"tags":[{"label":"CD11a-directed Humanized IgG1 Antibody","category":"class"},{"label":"Monoclonal Antibody","category":"modality"},{"label":"Leukocyte adhesion glycoprotein LFA-1 alpha","category":"target"},{"label":"ITGAL","category":"gene"},{"label":"L04AA21","category":"atc"},{"label":"Active","category":"status"},{"label":"Plaque psoriasis","category":"indication"},{"label":"Genentech","category":"company"},{"label":"Approved 2000s","category":"decade"}],"phase":"marketed","safety":{"safetySignals":[{"llr":98.702,"date":"","count":33,"signal":"Psoriasis","source":"DrugCentral FAERS","actionTaken":"Reported 33 times (LLR=99)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Roche","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=EFALIZUMAB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:29:03.316906+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:29:09.877193+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:29:03.390603+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EFALIZUMAB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:29:10.228859+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Integrin alpha-L/beta-2 (LFA-1) inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:29:11.262935+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201575/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:29:10.926866+00:00"}},"allNames":"hu1124","offLabel":[],"synonyms":["efalizumab","raptiva","hu1124","anti-CD11a","xanelim"],"timeline":[{"date":"2003-10-27","type":"positive","source":"DrugCentral","milestone":"FDA approval (Genentech)"},{"date":"2004-09-20","type":"positive","source":"DrugCentral","milestone":"EMA approval"}],"aiSummary":"Hu1124, also known as Efalizumab, is a CD11a-directed Humanized IgG1 Antibody developed by Genentech. It targets the leukocyte adhesion glycoprotein LFA-1 alpha, which plays a key role in the immune response. Efalizumab is approved for the treatment of plaque psoriasis and was first approved by the FDA in 2003. The commercial status of Efalizumab is patented, as it is still owned by Genentech. Key safety considerations include the risk of serious infections and the potential for reactivation of latent infections.","approvals":[{"date":"2003-10-27","orphan":false,"company":"GENENTECH","regulator":"FDA"},{"date":"2004-09-20","orphan":false,"company":"","regulator":"EMA"}],"brandName":"Hu1124","ecosystem":[{"indication":"Plaque psoriasis","otherDrugs":[{"name":"adalimumab","slug":"adalimumab","company":"Abbvie Inc"},{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"alefacept","slug":"alefacept","company":"Astellas"},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"}],"globalPrevalence":125000000}],"mechanism":{"target":"Leukocyte adhesion glycoprotein LFA-1 alpha","novelty":"Follow-on","targets":[{"gene":"ITGAL","source":"DrugCentral","target":"Leukocyte adhesion glycoprotein LFA-1 alpha","protein":"Integrin alpha-L"}],"moaClass":"CD11a-directed Antibody Interactions","modality":"Monoclonal Antibody","drugClass":"CD11a-directed Humanized IgG1 Antibody","explanation":"","oneSentence":"","technicalDetail":"Efalizumab is a CD11a-directed Humanized IgG1 Antibody that binds to the LFA-1 alpha subunit with high affinity, thereby inhibiting the interaction between LFA-1 and ICAM-1 and reducing the activation and migration of T cells through the endothelium."},"commercial":{"launchDate":"2003","_launchSource":"DrugCentral (FDA 2003-10-27, GENENTECH)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4959","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=EFALIZUMAB","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EFALIZUMAB","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T10:52:14.793085","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:29:12.613956+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"muromonab-CD3","drugSlug":"muromonab-cd3","fdaApproval":"1992-09-14","relationship":"same-class"},{"drugName":"mycophenolic acid","drugSlug":"mycophenolic-acid","fdaApproval":"2004-02-27","relationship":"same-class"},{"drugName":"sirolimus","drugSlug":"sirolimus","fdaApproval":"1999-09-15","patentExpiry":"Oct 28, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"leflunomide","drugSlug":"leflunomide","fdaApproval":"1998-09-10","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"alefacept","drugSlug":"alefacept","fdaApproval":"2003-01-30","relationship":"same-class"},{"drugName":"everolimus","drugSlug":"everolimus","fdaApproval":"2009-03-30","patentExpiry":"May 1, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"natalizumab","drugSlug":"natalizumab","fdaApproval":"2004-11-23","relationship":"same-class"},{"drugName":"abatacept","drugSlug":"abatacept","fdaApproval":"2005-12-23","relationship":"same-class"},{"drugName":"eculizumab","drugSlug":"eculizumab","fdaApproval":"2007-03-16","relationship":"same-class"},{"drugName":"belimumab","drugSlug":"belimumab","fdaApproval":"2011-03-09","relationship":"same-class"},{"drugName":"fingolimod","drugSlug":"fingolimod","fdaApproval":"2010-09-21","patentExpiry":"Sep 30, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"belatacept","drugSlug":"belatacept","fdaApproval":"2011-06-15","relationship":"same-class"},{"drugName":"tofacitinib","drugSlug":"tofacitinib","fdaApproval":"2012-11-06","patentExpiry":"Sep 14, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"teriflunomide","drugSlug":"teriflunomide","fdaApproval":"2012-09-12","patentExpiry":"Sep 14, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"apremilast","drugSlug":"apremilast","fdaApproval":"2014-03-21","patentExpiry":"Nov 29, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"vedolizumab","drugSlug":"vedolizumab","fdaApproval":"2014-05-20","relationship":"same-class"},{"drugName":"alemtuzumab","drugSlug":"alemtuzumab","fdaApproval":"2001-05-07","relationship":"same-class"},{"drugName":"ocrelizumab","drugSlug":"ocrelizumab","fdaApproval":"2017-03-28","relationship":"same-class"},{"drugName":"baricitinib","drugSlug":"baricitinib","fdaApproval":"2018-05-31","patentExpiry":"Nov 30, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ozanimod","drugSlug":"ozanimod","fdaApproval":"2020-03-25","patentExpiry":"Sep 30, 2038","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"efalizumab","indications":{"approved":[{"name":"Plaque psoriasis","source":"DrugCentral","snomedId":200965009,"regulator":"FDA","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"muromonab-cd3","brandName":"muromonab-CD3","genericName":"muromonab-CD3","approvalYear":"1992","relationship":"same-class"},{"drugId":"mycophenolic-acid","brandName":"mycophenolic acid","genericName":"mycophenolic acid","approvalYear":"2004","relationship":"same-class"},{"drugId":"sirolimus","brandName":"sirolimus","genericName":"sirolimus","approvalYear":"1999","relationship":"same-class"},{"drugId":"leflunomide","brandName":"leflunomide","genericName":"leflunomide","approvalYear":"1998","relationship":"same-class"},{"drugId":"alefacept","brandName":"alefacept","genericName":"alefacept","approvalYear":"2003","relationship":"same-class"},{"drugId":"everolimus","brandName":"everolimus","genericName":"everolimus","approvalYear":"2009","relationship":"same-class"},{"drugId":"natalizumab","brandName":"natalizumab","genericName":"natalizumab","approvalYear":"2004","relationship":"same-class"},{"drugId":"abatacept","brandName":"abatacept","genericName":"abatacept","approvalYear":"2005","relationship":"same-class"},{"drugId":"eculizumab","brandName":"eculizumab","genericName":"eculizumab","approvalYear":"2007","relationship":"same-class"},{"drugId":"belimumab","brandName":"belimumab","genericName":"belimumab","approvalYear":"2011","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01848028","phase":"","title":"PsoBest - The German Psoriasis Registry","status":"RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2008-01","conditions":["Psoriasis","Psoriatic-arthritis"],"enrollment":3500,"completionDate":"2032-12"},{"nctId":"NCT02075697","phase":"","title":"Spanish Registry of Systemic Treatments in Psoriasis","status":"UNKNOWN","sponsor":"Fundación Academia Española de Dermatología","startDate":"2008-10","conditions":["Psoriasis"],"enrollment":3500,"completionDate":"2025-10"},{"nctId":"NCT00115076","phase":"PHASE3","title":"Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2003-08-04","conditions":["Psoriasis"],"enrollment":31,"completionDate":"2011-04-06"},{"nctId":"NCT00501709","phase":"PHASE1,PHASE2","title":"Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2007-02","conditions":["Type 1 Diabetes"],"enrollment":10,"completionDate":"2016-12"},{"nctId":"NCT00308204","phase":"PHASE2","title":"Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva","status":"WITHDRAWN","sponsor":"The Cleveland Clinic","startDate":"2006-03","conditions":["Discoid Lupus Erthematosus of the Scalp"],"enrollment":0,"completionDate":"2007-08"},{"nctId":"NCT00226057","phase":"PHASE1","title":"Efalizumab for Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2005-06","conditions":["Dermatitis, Atopic"],"enrollment":10,"completionDate":"2006-05"},{"nctId":"NCT00368654","phase":"PHASE1,PHASE2","title":"Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2007-01","conditions":["Psoriasis"],"enrollment":12,"completionDate":"2008-05"},{"nctId":"NCT00287118","phase":"PHASE4","title":"A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-10-27","conditions":["Candidates for Systemic Therapy for Psoriasis","Psoriasis"],"enrollment":189,"completionDate":"2006-05-30"},{"nctId":"NCT00249808","phase":"PHASE4","title":"A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-12-13","conditions":["Psoriasis"],"enrollment":1266,"completionDate":"2007-01-25"},{"nctId":"NCT00672204","phase":"PHASE1,PHASE2","title":"Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2007-11","conditions":["Type 1 Diabetes Mellitus","Hypoglycemia"],"enrollment":23,"completionDate":"2012-08"},{"nctId":"NCT00729768","phase":"PHASE2,PHASE3","title":"A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation","status":"WITHDRAWN","sponsor":"Genentech, Inc.","startDate":"","conditions":["Kidney Transplantation"],"enrollment":0,"completionDate":""},{"nctId":"NCT00669214","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2008-02","conditions":["Psoriasis"],"enrollment":89,"completionDate":"2009-01"},{"nctId":"NCT00489216","phase":"NA","title":"Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids","status":"TERMINATED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2006-12","conditions":["Graft Versus Host Disease"],"enrollment":2,"completionDate":"2008-10"},{"nctId":"NCT00312026","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-03-30","conditions":["Psoriasis"],"enrollment":75,"completionDate":"2006-11-28"},{"nctId":"NCT00256139","phase":"PHASE3","title":"CLEAR Study: Clinical Experience Acquired With Raptiva Study","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2003-03","conditions":["Moderate to Severe Psoriasis"],"enrollment":793,"completionDate":"2004-10"},{"nctId":"NCT00442650","phase":"PHASE3","title":"Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-01","conditions":["Moderate to Severe Psoriasis"],"enrollment":0,"completionDate":"2005-12"},{"nctId":"NCT00676559","phase":"PHASE1","title":"Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2008-04","conditions":["Diabetic Macular Edema"],"enrollment":0,"completionDate":"2010-04"},{"nctId":"NCT00276250","phase":"PHASE2","title":"Islet Transplantation Using Abatacept","status":"COMPLETED","sponsor":"Emory University","startDate":"2005-12","conditions":["Type 1 Diabetes Mellitus"],"enrollment":5,"completionDate":"2014-12"},{"nctId":"NCT00746980","phase":"PHASE2","title":"Efalizumab in the Treatment of Alopecia, Phase II","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2008-08","conditions":["Alopecia Totalis"],"enrollment":0,"completionDate":"2009-07"},{"nctId":"NCT00344448","phase":"PHASE2","title":"Pilot Study of Raptiva to Treat Sjogren's Syndrome","status":"TERMINATED","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","startDate":"2006-06","conditions":["Sjogren's Syndrome"],"enrollment":10,"completionDate":"2009-01"},{"nctId":"NCT00254982","phase":"PHASE3","title":"Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-08","conditions":["Psoriasis"],"enrollment":593,"completionDate":"2006-09"},{"nctId":"NCT00336973","phase":"PHASE4","title":"A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-05","conditions":["Psoriasis"],"enrollment":73,"completionDate":""},{"nctId":"NCT00726466","phase":"PHASE1","title":"Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration","status":"WITHDRAWN","sponsor":"Vitreous -Retina- Macula Consultants of New York","startDate":"2008-03","conditions":["Age Related Macular Degeneration","AMD","CNV"],"enrollment":0,"completionDate":""},{"nctId":"NCT00096928","phase":"","title":"A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2005-03","conditions":["Psoriasis"],"enrollment":1846,"completionDate":"2009-10"},{"nctId":"NCT00402818","phase":"","title":"RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2006-05","conditions":["Plaque Psoriasis"],"enrollment":294,"completionDate":"2009-07"},{"nctId":"NCT00737763","phase":"PHASE2","title":"Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2008-10","conditions":["Diabetes Mellitus, Type 1"],"enrollment":0,"completionDate":"2009-11"},{"nctId":"NCT00096603","phase":"PHASE3","title":"A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2002-10","conditions":["Psoriasis"],"enrollment":450,"completionDate":"2004-07"},{"nctId":"NCT00338143","phase":"PHASE3","title":"A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2003-10","conditions":["Psoriasis"],"enrollment":1200,"completionDate":"2004-05"},{"nctId":"NCT00739882","phase":"PHASE4","title":"TRUST Study: Raptiva ® in Hand & Foot Psoriasis","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-04","conditions":["Chronic Plaque Psoriasis"],"enrollment":76,"completionDate":"2009-06"},{"nctId":"NCT01079988","phase":"PHASE4","title":"Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-02","conditions":["Psoriasis"],"enrollment":41,"completionDate":"2005-04"},{"nctId":"NCT00697593","phase":"PHASE4","title":"ChangE From Any Systemic psoriasiS therapY to Raptiva","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-01","conditions":["Chronic Plaque Psoriasis"],"enrollment":70,"completionDate":"2009-04"},{"nctId":"NCT00972543","phase":"PHASE4","title":"Raptiva in Palm and Sole Psoriasis","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-09","conditions":["Chronic Plaque Psoriasis"],"enrollment":6,"completionDate":""},{"nctId":"NCT00472082","phase":"PHASE1,PHASE2","title":"Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients","status":"TERMINATED","sponsor":"Emory University","startDate":"2007-05","conditions":["Kidney Transplantation","Chronic Kidney Failure"],"enrollment":5,"completionDate":"2009-04"},{"nctId":"NCT00096980","phase":"PHASE4","title":"A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2001-02","conditions":["Psoriasis"],"enrollment":300,"completionDate":"2004-05"},{"nctId":"NCT00109252","phase":"PHASE3","title":"A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2002-01","conditions":["Psoriasis"],"enrollment":0,"completionDate":"2003-04"},{"nctId":"NCT00109317","phase":"PHASE3","title":"A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2002-09","conditions":["Psoriasis"],"enrollment":686,"completionDate":"2003-02"},{"nctId":"NCT00777400","phase":"PHASE1,PHASE2","title":"Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2008-12","conditions":["Autoimmune Diseases"],"enrollment":0,"completionDate":"2009-04"},{"nctId":"NCT00608777","phase":"PHASE4","title":"Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)","status":"TERMINATED","sponsor":"Derm Research, PLLC","startDate":"2008-01","conditions":["Plaque Psoriasis"],"enrollment":6,"completionDate":"2009-02"},{"nctId":"NCT00184366","phase":"","title":"Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis","status":"TERMINATED","sponsor":"Norwegian University of Science and Technology","startDate":"2005-05","conditions":["Plaque Psoriasis"],"enrollment":96,"completionDate":"2008-07"},{"nctId":"NCT00133107","phase":"NA","title":"Safety and Effectiveness of Efalizumab to Treat Oral Lichen Planus","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2005-01","conditions":["Lichen Planus, Oral"],"enrollment":4,"completionDate":"2005-11"},{"nctId":"NCT00280826","phase":"PHASE1","title":"Efalizumab to Treat Uveitis","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2006-01","conditions":["Uveitis","Macular Edema"],"enrollment":6,"completionDate":"2009-02"},{"nctId":"NCT00097240","phase":"","title":"An Observational Study of the Use and Safety of Raptiva During Pregnancy (FOLLOW)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2005-01","conditions":["Psoriasis","Pregnancy"],"enrollment":18,"completionDate":"2009-09"},{"nctId":"NCT00510536","phase":"PHASE4","title":"Treatment of Mild to Moderate Joint Pain in Patients With Chronic Plaque Psoriasis Receiving Efalizumab","status":"COMPLETED","sponsor":"Probity Medical Research","startDate":"2007-07","conditions":["Arthritis","Arthralgia"],"enrollment":50,"completionDate":"2008-10"},{"nctId":"NCT00146003","phase":"PHASE2","title":"Efalizumab for Eczema","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2005-03","conditions":["Dermatitis, Atopic"],"enrollment":10,"completionDate":"2007-12"},{"nctId":"NCT00707070","phase":"PHASE4","title":"Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis","status":"UNKNOWN","sponsor":"Universita di Verona","startDate":"2008-09","conditions":["Chronic Plaque Psoriasis"],"enrollment":100,"completionDate":"2009-10"},{"nctId":"NCT00602823","phase":"","title":"Genomic Study for the Prediction of Efficacy and Adverse Effects of CD11a Monoclonal Antibodies(Raptiva)","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2006-02","conditions":["Psoriasis"],"enrollment":20,"completionDate":"2006-05"},{"nctId":"NCT00302445","phase":"PHASE4","title":"A Safety and Efficacy Study to Evaluate Efalizumab in Combination With UVB for Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"Derm Research, PLLC","startDate":"2006-03","conditions":["Plaque Psoriasis"],"enrollment":20,"completionDate":"2007-07"},{"nctId":"NCT00382512","phase":"PHASE1","title":"A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2003-05","conditions":["Plaque Psoriasis"],"enrollment":60,"completionDate":""},{"nctId":"NCT00134134","phase":"PHASE1","title":"Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2005-02","conditions":["Hidradenitis Suppurativa"],"enrollment":5,"completionDate":"2006-08"},{"nctId":"NCT00034203","phase":"PHASE2","title":"Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.","status":"COMPLETED","sponsor":"XOMA (US) LLC","startDate":"2002-04","conditions":["Rheumatoid Arthritis"],"enrollment":0,"completionDate":"2003-08"},{"nctId":"NCT00051662","phase":"PHASE1","title":"Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis","status":"COMPLETED","sponsor":"XOMA (US) LLC","startDate":"","conditions":["Psoriatic Arthritis"],"enrollment":45,"completionDate":"2004-02"}],"_emaApprovals":[{"date":"2004-09-20","status":"Authorised","company":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000148826","MMSL":"17649","NDDF":"005208","UNII":"XX2MN88N5D","VUID":"4021411","VANDF":"4021411","INN_ID":"8122","RXNORM":"356988","UMLSCUI":"C1174995","chemblId":"CHEMBL1201575","ChEMBL_ID":"CHEMBL1201575","KEGG_DRUG":"D03959","DRUGBANK_ID":"DB00095","SNOMEDCT_US":"407005009","IUPHAR_LIGAND_ID":"6593","MESH_SUPPLEMENTAL_RECORD_UI":"C472181"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2003-","companyName":"Roche","relationship":"Original Developer"}],"publicationCount":586,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"L04AA21","allCodes":["L04AA21"]},"biosimilarFilings":[],"originalDeveloper":"Genentech","recentPublications":[{"date":"2025 Nov 10","pmid":"41409530","title":"Immune Cell-Targeting Biologics for Alopecia Areata: A New Paradigm in Precision Medicine.","journal":"Skin appendage disorders"},{"date":"2025 Nov","pmid":"40856907","title":"Management of Erythrodermic Psoriasis with Systemic Therapies: A Systematic Review.","journal":"American journal of clinical dermatology"},{"date":"2025 Apr 16","pmid":"40220275","title":"Drug-induced Guillain-Barré Syndrome: a disproportionality analysis based on the US FDA adverse event reporting system.","journal":"Expert opinion on drug safety"},{"date":"2024","pmid":"39411068","title":"PBPK-based translation from preclinical species to humans for the full-size IgG therapeutic efalizumab.","journal":"Frontiers in pharmacology"},{"date":"2023","pmid":"37496824","title":"Effect of Biologic Therapies on Airway Hyperresponsiveness and Allergic Response: A Systematic Literature Review.","journal":"Journal of asthma and allergy"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","companyName":"Roche","companyId":"roche","modality":"Monoclonal antibody","firstApprovalDate":"2003","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2003-10-27T00:00:00.000Z","mah":"GENENTECH","brand_name_local":null,"application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:29:12.613956+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}